Liver cancer is the second leading cause of cancer mortality worldwide, causing more than
700,000 deaths annually. Because of the wide landscape of genomic alterations and limited …

Cholangiocarcinomas (CCAs) are hepatobiliary cancers with features of cholangiocyte
differentiation; they can be classified anatomically as intrahepatic CCA (iCCA), perihilar …

Platelet-derived growth factor (PDGF) isoforms and PDGF receptors have important
functions in the regulation of growth and survival of certain cell types during embryonal …

Background Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for
patients with advanced biliary tract cancer; expression of VEGF and its receptors is …

Platelet‐derived growth factor (PDGF) isoforms and their receptors have important roles
during embryogenesis, particularly in the development of various mesenchymal cell types in …

Cholangiocarcinoma (CCA) is a rare malignancy that develops at any point along the biliary
tree. CCA has a poor prognosis, its clinical management remains challenging, and effective …

Cholangiocarcinomas are usually characterized by a prominent desmoplastic and
hypovascularized stroma. However, the biological significance and clinical impact of the …

Background Since sorafenib has shown activity in different tumour types and gemcitabine
regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line …

Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy with limited treatment
options and low survival rates. Currently, there are no curative medical therapies for CCA …

Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy with a poor overall
prognosis. There is a critical need to develop effective targeted therapies for the treatment of …